Mettler-Toledo International Inc. (MTD) | The Buildout — AI Infrastructure

——Mkt cap — · 52-wk —–— · YTD — · delayed

Updated Aug 12, 2026Q2 FY2026 reviewed

Mettler-Toledo makes precision instruments and process analytics used in semiconductor fabs and data-center cooling loops.

Organic +4%

Q2 FY2026 organic local-currency growth, up from +1% in Q1.

China +9%

China organic growth in Q2; FY outlook raised to high single digit.

Service $1B+

Service revenue crossed $1B last year; Q2 +9% local currency.

~1.5 mo backlog

Short-cycle visibility; forecast relies on pipeline conversion.

The Buildout Takeaway

The quarter showed customers spending again after Q1 pushouts, but management kept the second-half outlook mostly unchanged, treating the beat as a buffer rather than a new trend. The open question is whether the recovery can persist without a contracted backlog.

Analyst coverage

19 analysts·8 Buy11 Hold0 Sell

Median target$1,512 Range $1,194–$1,600 · 7 estimates

Management guidance

FY2026 local-currency sales growth ~4%–5% · organic growth 3%–4% · adjusted EPS $47.15–$47.50 · free cash flow ~$900M · China high single digit

Important: The Buildout is a data analytics platform. Content is generated by algorithms and AI agents using public filings, earnings transcripts, and market data. This is not personalized investment advice.

Our View

The Verdict

Mettler-Toledo manufactures precision instruments and services for laboratories and industrial production. Its most direct AI-infrastructure role is Process Analytics equipment used in semiconductor fabs and data-center cooling systems. LabX software connects many QA/QC lab instruments and gives customers an optional path to aggregate data for AI. The company does not present itself as an AI company; AI appears as an enabling layer inside products and its service operations.

Market Cap	—
Revenue (TTM)	$4.1B
Revenue Growth	+6.9%
EBITDA Margin (TTM)	31.9%

Net Debt	$2.1B
Earnings Beats	7 of 7
P/E (TTM)	—
EV/EBITDA (TTM)	—

What We Like

Service exceeded $1 billion in revenue for the first time in the prior year and is growing high-single digit; management estimates a $3 billion serviceable installed base with about $1 billion penetrated.
Roughly 50% of sales go into production and about 20% into QA/QC, positioning the company for reshoring and biopharma capital-expenditure demand.
Management says MTD provides about 40% of the instruments in a typical QA/QC lab, most connected to LabX software, an AI-ready data and workflow position.
Emerging markets outside China are about 18% of Q2 sales, slightly more than China, and have grown high single digits on average over the last five years.
Pricing realization was about 3% in Q2 and the full-year assumption is approaching 3%, with the long-term assumption around 2%.

What We’re Watching

H2 2026 pipeline conversion: management says customers have budgets, but with only ~1.5 months of backlog the recovery is not contracted.
Product Inspection reacceleration is guided from +1% organic in Q2 to mid-single-digit in Q3; full-year guide is high single digit reported and mid-single digit organic.
Reshoring is early innings: RFQ activity is visible, but management expects larger instrumentation demand only in 2027–2028.
Tariff and refund complexity: Q2 included a $52M gross IEEPA refund benefit and a $28M customer refund; guidance assumes tariffs return to prior levels in H2.

Bottom Line

The near-term operating picture is strengthening: Q2 organic growth reaccelerated from +1% to +4%, and full-year sales and EPS guidance were raised, but the raise mostly captured the Q2 beat rather than re-rating the second half. The open question is whether the recovery is a durable broadening across China, Laboratory, and service, or a one-quarter release of delayed Q1 demand.

Next upQ3 2026 results are the next major test, guided to ~4% local-currency sales growth and adjusted EPS of $12.00–$12.15. The report will show whether Q2 momentum held or was partly catch-up from Q1 delays.

Last Quarter — Q2 FY2026

Earnings Beat

Q2 FY2026 revenue was $1,027.3 million, reported gross margin was 63.3%, and EBITDA was $339.4 million. Adjusted gross margin was 59.3%, up 90 basis points excluding foreign currency and acquisitions, and adjusted operating margin was 29.3%, up 100 basis points ex-FX. Adjusted EPS was $11.46, up 14% year over year.

Metric	Q2 FY2026	Q1 FY2026	Q2 FY2025	YoY
Revenue	$1.0B	$947M	$983M	+4.5%
Gross margin	63.3%	58.7%	57.2%	+610bps
EBITDA	$339M	$279M	$296M	+14.6%
EPS	$11.53	$8.35	$9.73	+18.5%
Organic local-currency sales growth	+4%	+1%	n/a	—

Our second quarter results were strong and reflected better-than-expected organic sales growth across our portfolio, including very good growth in China and emerging markets.— Patrick Kaltenbach, Chief Executive Officer, July 31, 2026

Management tone: Management's tone shifted from cautious on Q1 to clearly positive on Q2, describing strong results and good momentum. The CFO acknowledged that the full-year raise mostly captured the Q2 beat and retained 'a little bit of conservatism or moderation slightly' as a geopolitical buffer. Management attributed China strength to Industrial double-digit growth and quantified bioprocessing as low-double-digit of total sales and chemicals as under 15% of sales.

Management Guidance

Full-year local-currency sales growth was raised to ~4% to 5%, with organic growth of 3% to 4%. Adjusted EPS was raised to $47.15–$47.50, representing 10–11% growth, or 11–12% excluding currency. Q3 is initiated at ~4% local-currency sales growth and adjusted EPS of $12.00–$12.15. Management assumes IEEPA tariffs return to prior levels in H2 and excludes future refunds. Full-year pricing is now approaching 3%, free cash flow is reaffirmed at ~$900 million, and repurchases are increased to ~$875 million.

Business Trajectory

Trajectory

Reported revenue was $947.1 million in Q1 FY2026, up 7.2% year over year, then $1,027.3 million in Q2 FY2026, up 4.5% year over year; the reported year-over-year pace slowed. Management's operating view strips out currency and the IEEPA tariff refund: organic local-currency growth accelerated from +1% in Q1 to +4% in Q2. Reported gross margin jumped from 58.7% to 63.3%, helped by the tariff refund, while adjusted gross margin was 59.3%, up 90 basis points ex-FX/acquisitions.

Revenue & Margin Trajectory

Gross margin as reported.

Share Price — 12 Months

52-week range $1,026–$1,492.

Share Price — 12 Months

52-week range $1,026–$1,492.

The Numbers

The Model

The model's locked FY+1 projection is revenue of $4,285 million and EBITDA of $1,354 million, a 31.6% margin. FY+2 is projected at $4,520 million of revenue and $1,451 million of EBITDA, a 32.1% margin. Near-term revenue is anchored by management's full-year local-currency growth guide of ~4% to 5%; the FY+2 path assumes continued service growth and modest margin expansion.

Revenue & EBITDA Projections

Solid bars are reported actuals; outlined bars are model projections — not company guidance.

Metric	FY2025	Next FY (E)	Following FY (E)
Revenue	$4.0B	$4.3B	$4.5B
YoY Growth	—	+6.4%	+5.5%
EBITDA	$1.2B	$1.4B	$1.5B
EBITDA Margin	30.9%	31.6%	32.1%

Projections are the median of 5 independent model runs. The model’s revenue sits 1.9% above analyst consensus.

What Could Go Right — and Wrong

What good looks like

China sustains high-single-digit growth and Laboratory joins the Industrial recovery, rather than fading after a strong quarter.
Lab replacement demand becomes an actual cycle, supported by USP, Japanese, and China Pharmacopeia revisions.
Reshoring converts earlier than expected, with RFQ activity turning into orders ahead of the 2027–2028 timeline.
Process Analytics in semiconductor and data-center cooling grows from low single digit to a clearly visible contributor.
LabX connectivity begins to monetize through workflow/data services or AI-enabled lab workflows.

What could go wrong

Middle East escalation or a new macro shock causes a repeat of Q1-style budget freezes and pushouts.
China's battery/industrial investment moderates, removing the company's strongest geography.
Q2 organic acceleration was partly catch-up from delayed Q1 projects, and underlying organic growth settles back toward 1–2%.
Tariff refund effects reverse or become a customer/supplier obligation drag, with IEEPA tariffs returning in H2 as assumed.
Product Inspection and food manufacturing softness turns the H2 reacceleration into another project-timing miss.

What’s Next

Looking Ahead

The next twelve months hinge on H2 2026 conversion. Q3 is guided to ~4% local-currency sales growth and adjusted EPS of $12.00–$12.15, with China expected to grow high single digit and Product Inspection guided to reaccelerate to mid-single-digit growth. Beyond 2026, management expects reshoring RFQs to convert into larger instrumentation demand in 2027–2028, and an Analyst Day is planned, though a date was not given.

Catalysts

Q3 2026Q3 2026 earnings report — Tests ~4% LC sales growth and $12.00–$12.15 adjusted EPS.
H2 2026Product Inspection reacceleration — Guided mid-single Q3; full-year high single reported / mid-single organic.
FY 2026Full-year guidance delivery — Tests 4–5% LC growth, 3–4% organic, ~$900M free cash flow.
H2 2026Pipeline and order conversion — Short-cycle visibility: watch whether Q2 momentum holds.
2027–2028Reshoring/onshoring order conversion — Larger instrumentation demand expected from facility investments.

Numbers

Financials

Annual Summary

Metric	FY2024	FY2025	TTM	YoY
Revenue	$3.9B	$4.0B	$4.1B	+4.0%
Gross Margin	58.1%	57.5%	59.3%	62bps
EBITDA	$1.3B	$1.2B	$10.2B	-0.5%
EBITDA Margin	32.3%	30.9%	31.9%	139bps
Net Income	$863M	$869M	$906M	+0.7%
Free Cash Flow	$864M	$849M	$6.7B	—
Net Cash	—	—	—	—

Key Ratios (Trailing)

Valuation

P/E TTM—
EV/EBITDA TTM—
EV/Revenue TTM—
Price/FCF TTM—

Profitability

Gross Margin (TTM)59.3%
EBITDA Margin (TTM)31.9%
Net Margin (TTM)21.9%
ROIC45.2%
FCF Conversion65.6%
SBC / Revenue0.6%

Reference

The Company

Mettler-Toledo makes precision instruments and services used across laboratories and industrial production, including balances, pipettes, titrators, pH meters, thermal analysis, process analytics, weighing terminals, metal detectors, X-ray systems, and food-retail weighing. The 10-K describes it as a leading global supplier with products sold in more than 140 countries and a direct presence in about 40 countries. Management says roughly 50% of sales go into production and about 20% into QA/QC.

The company operates a global manufacturing and shared-service footprint spanning Switzerland, the U.K., Germany, Poland, the U.S., Mexico, China, India, and Malaysia. It has developed local assembly and manufacturing in Mexico, and a Shanghai-area capacity expansion is supported by a $6 million local-government grant. The business is short-cycle, carrying only about 1.5 months of backlog.

Business Segments

Laboratory

Q2 organic +4%

Balances, pipettes, titrators, pH meters, thermal analysis, UV/VIS, moisture analyzers, cell counters, and LabX software.

Growth driver: Pharmacopeia revisions and biopharma/bioprocessing demand.

Core Industrial

Q2 organic +4%

Weighing terminals, scales, weigh modules, automation, dimensioning and data capture, and vehicle scales.

Growth driver: Automation and digitalization across biopharma, food, semiconductor,

Product Inspection

Q2 organic +1%; FY guide high single reported / mid-single organic

Metal detectors, X-ray systems, checkweighers, camera-based inspection; about 70% food manufacturing.

Growth driver: New products and mid-market positioning; H2 project timing.

Competitive Landscape

Mettler-Toledo describes itself as a leading global supplier and says it believes it holds global number-one market positions in most of its businesses. The provided source material does not name company-disclosed competitors.

Supply Chain

MTD sits between component suppliers and laboratory/industrial end users. The 10-K discloses limited/single-source reliance but names no suppliers, and no specific customer names are disclosed in the source material.